Glucagon-like peptide 1 protects microvascular endothelial cells by inactivating the PARP-1/iNOS/NO pathway

Molecular and Cellular Endocrinology

Volumn 339, Issue 1-2, 2011, Pages 25-33

  Liu, Fu qiang ^a   Zhang, Xiang li ^a   Gong, Lei ^a   Wang, Xu ping ^a   Wang, Juan ^a   Hou, Xin guo ^a   Sun, Yu ^a   Qin, Wei dong ^a   Wei, Shu jian ^a   Zhang, Yun ^a   Chen, Li ^a   Zhang, Ming Xiang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

GLP 1 receptor; Glucagon like peptide 1 (GLP 1); INOS; Islet microvascular endothelial cells; Oxidized low density lipoprotein; PARP 1

Indexed keywords

3 NITROTYROSINE; ANTIOXIDANT; CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; CELL PROTECTION; CELL STRAIN MS 1; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; IN VITRO STUDY; LIPID PEROXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CYCLIC AMP; ENDOTHELIAL CELLS; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPOPROTEINS, LDL; MICE; MICROVESSELS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; POLY(ADP-RIBOSE) POLYMERASES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 79958023978     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.03.007     Document Type: Article

References (33)

1. Ballian N., Brunicardi F.C. Islet vasculature as a regulator of endocrine pancreas function. World J. Surg. 2007, 4:705-714.
2. Baumgartner-Parzer S.M., Wagner L., Pettermann M., Grillari J., Gessl A., Waldhäusl W. High-glucose-triggered apoptosis in cultured endothelial cells. Diabetes 1995, 44:1323-1327.
3. Bonner-Weir S., Go V.L.W., Dimagno E.P., Gardner J.D., Lebenthal E., Reber H.A., Scheele G.A. The pancreas. Biology, pathobiology and disease. The Microvasculature of the Pancreas, with Special Emphasis on that of the Islets of Langerhans. Anatomy and Functional Implications 1993, Raven Press, New York, pp 759-768.
4. Brubaker P.L., Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon like peptide-2. Can. J. Physiol. Pharm. 2003, 81:1005-1012.
5. Cines D.B., Pollak E.S., Buck C.A., Loscalzo J., Zimmerman G.A., McEver R.P., Pober J.S., Wick T.M., Konkle B.A., Schwart B.S., Barnathan E.S., McCrae K.R., Hug B.A., Schmidt A.M., Stern D.M. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
6. Donath M.Y., Halban P.A. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 2004, 47:581-589.
7. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002, 122:531-544.
8. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
9. Dweik R.A. Nitric oxide, hypoxia, and superoxide: the good, the bad, and the ugly!. Thorax 2005, 60:265-267.
10. Erdogdua Ö., Nathansonb D., Sjöholmb Å., Nyströmb T., Zhanga Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol. Cell. Endocrinol. 2010, 325:26-35.
11. Goligorsky M.S., Chen J., Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension 2001, 37(2):744-748.
12. Ho F.M., Liu S.H., Liau C.S., Huang P.J., Lin-Shiau S.Y. High glucose induced apoptosis in human endothelial cells is mediated by sequential activations of c-Jun NH(2)-terminal kinase and caspase-3. Circulation 2000, 101:2618-2624.
13. Imrie H., Abbas A., Kearney M. Insulin resistance, lipotoxicity and endothelial dysfunction. Biochim. Biophys. Acta 2010, 3:320-326.
14. Ido Y., Carling D., Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002, 51:159-167.
15. Juul Holst J., Vilsbøll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell. Endocrinol. 2009, 297:127-136.
16. Kim M.J., Ryu G.R., Kang J.H., Sim S.S., Min D.S., Rhie D.J., Yoon S.H., Hahn S.J., Jeong I.K., Hong K.J., Kim M.S., Jo Y.H. Inhibitory effects of epicatechin on interleukin-1-induced inducible nitric oxide synthase expression in RINm5F cells and rat pancreatic islets by down-regulation of NF-kB activation. Biochem. Pharmacol. 2004, 68:1775-1785.
17. Konstantinova I., Lammert E. Microvascular development: learning from pancreatic islets. Bioessays 2004, 26:1069-1075.
18. Lammert E., Cleaver O., Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science 2001, 294:564-567.
19. Lorenzi M., Cagliero E. Pathobiology of endothelial and other vascular cells in diabetes mellitus. Call for data. Diabetes 1991, 40:653-659.
20. Nakhjavani M., Khalilzadeh O., Khajeali L., Esteghamati A., Morteza A., Jamali A., Dadkhahipour S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010, 45(April (4)):321-327.
21. Naura A.S., Datta R., Hans C.P. Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia. Eur. Respir. J. 2009, 33:252-261.
22. Nystrom T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm. Metab. Res. 2008, 40:593-606.
23. Nystrom T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahren B., Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E1209-E1215.
24. Olsson R., Carlsson P.O. The pancreatic islet endothelial cell: emerging roles in islet function and disease. Int. J. Biochem. Cell Biol. 2006, 38:492-497.
25. Redington A.E. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur. J. Pharmacol. 2006, 533:263-276.
26. Sakamoto C., Goldfine I.D., Roach E., Williams J.A. Localization of saturable CCK binding sites in rat pancreatic islets by light and electron microscope autoradiography. Diabetes 1985, 34:390-394.
27. Salehi A., Ekelund M., Lundquist I. Total parenteral nutrition-stimulated activity of inducible nitric oxide synthase in rat pancreatic islets is suppressed by glucagon-like peptide-1. Horm. Metab. Res. 2003, 35:48-54.
28. Salehi A., Meidute Abaraviciene S., Jimenez-Feltstrom J. Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1. PLoS One 2008, 3(5):e2165.
29. Szabo C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic. Biol. Med. 1996, 21:855-869.
30. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 3(53 Suppl.):S16-S21.
31. Yan M.-X., Li Y.-Q., Min Meng A. Long-term high-fat diet induces pancreatic injuries via pancreatic microcirculatory disturbances and oxidative stress in rats with hyperlipidemia. BBRC 2006, 347:192-199.
32. Yu Z., Kuncewicz T., Dubinsky W.P., Kone B.C. Nitric oxide-dependent negative feedback of PARP-1 trans-activation of the inducible nitric-oxide synthase gene. JBC 2006, 14:9101-9109.
33. Zanone M.M., Favaro E., Camussi G. From endothelial to Beta cells: insights into pancreatic islet microendothelium. Curr. Diabetes Rev. 2008, 4:1-9.